Kiniksa Pharmaceuticals International, plc — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kiniksa reported Q2 2026 ARCALYST net product revenue of $243.6 million (55% YoY growth), prompting a raise of full-year 2026 ARCALYST guidance to $980–995 million from prior guidance of $930–945 million. As of Q2 end, ~21% of 14,000 multiple-recurrence patients were on ARCALYST; KPL-387 Phase 2 data showed rapid pain/inflammation reduction at 300 mg monthly dose, with Phase 3 trial (PASTORALE) now enrolling ~85 patients. Company reported Q2 net income of $25.4 million and maintains $525.9 million cash with no debt.
Why this rating
Strong revenue beat ($50M+ guidance increase, ~5% of $1.1B market cap) and robust commercial execution on largest asset. Pipeline advancement meaningful but early-stage. Cash position solid.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.